Abstract. RagD is a member of the small G protein family, which encodes a recently discovered activator of the mTOR pathway. In vitro, RagD plays an important role in the proliferation of NRF2 gene (NFE2L2) mutated cancer cells. We hypothesized that tumor RagD expression may be correlated with the mutation status of NRF2 in lung cancers. RagD mRNA levels were analyzed by quantitative real-time polymerase chain reaction (qPCR) in 90 surgically-treated lung squamous cell cancer cases, including 14 NRF2 mutation cases, and normalized by β-actin mRNA levels. Mean RagD/β-actin mRNA levels of lung squamous cell carcinoma patients did not differ with age (≤65 vs. >65), Brinkman index (<400 vs. ≥400) or gender. RagD/β-actin mRNA levels were significantly higher in stage III samples (3.204±3.623) compared to stage I samples (1.357±1.560) (P= 0.0039). In addition, higher RagD/β-actin mRNA levels were identified in NRF2 mutant samples (3.107±3.633) compared to wild-type samples (1.774±2.301) (P= 0.074). These results suggest that RagD induction by NRF2 activation plays a role in the proliferation of lung squamous cell cancers.
Introduction
Despite recent improvements in diagnosis, lung cancer is a major cause of mortality from malignant diseases due to its high incidence, malignant behavior and lack of major advancements in treatment strategy (1) . Although there have been advances in understanding the biology of lung cancer and introduction of new chemotherapeutic agents for treatment, the 5-year survival rate remains less than 15% (2) . Recently, progression in understanding oncogenic kinase signaling pathways has provided more successful targets for developing effective therapeutic strategies (3) , which may improve the outcome of lung cancer.
A potential therapeutic target is the mammalian target of rapamysin (mTOR) pathway, which plays a central role in regulating cell functions, including proliferation, growth, survival, mobility and angiogenesis (4, 5) . Dysregulation of the mTOR pathway has been reported in lung cancers (6, 7) . A member of the small G protein family, RagD, which encodes a recently discovered activator of the mTOR pathway (8), was significantly upregulated in cells expressing mutant NRF2 (9) . It has been demonstrated that mutations of the NRF2 gene (NFE2L2) are associated with primary lung cancer (10) (11) (12) (13) . It has also been revealed that patients with lung tumors containing the NRF2 gene mutation display a poorer prognosis compared to patients with non-mutant tumors (11, 12) . Additionally, NRF2 gene somatic mutation is more common in lung squamous cell carcinomas (11) .
Although we have revealed the NRF2 gene mutation status in lung cancer (11) , the correlation between NRF2 gene mutation and RagD expression status in lung cancer has not been reported. To determine the RagD mRNA expression status, we performed quantitative real-time polymerase chain reaction (qPCR) using a LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). The findings were compared to the clinicopathological features of lung squamous cell carcinomas.
19 were stage II and 24 were stage III. All patient samples were sequenced for the NRF2 gene (11) and 14 cases were positive for the NRF2 gene mutation.
PCR assays for NRF2. Total RNA was extracted from lung cancer tissues using an Isogen kit (Nippon Gene Co., Ltd., Tokyo, Japan) according to the manufacturer's instructions. RNA concentration was determined using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc., Rockland, DE, USA). Approximately 5 cases were excluded from each assay due to the an insufficient number of tumor cells to effectively extract tumor RNA. RNA (1 µg) was reverse transcribed using a First-Strand cDNA synthesis kit with 0.5 µg oligo(dT) 16 (Roche Diagnostics GmbH) according to the manufacturer's instructions. The reaction mixture was incubated at 25˚C for 15 min, 42˚C for 60 min, 99˚C for 5 min and then at 4˚C for 5 min. The cDNA concentration was also determined using a NanoDrop ND-1000 Spectrophotometer. Approximately 200 ng of each cDNA was used for PCR analysis. To ensure the accuracy of mRNA extraction and reverse transcription, all samples were subjected to PCR amplification using a β-actin primers kit (Nihon Gene Research Laboratory, Miyagi, Japan) and a LightCycler FastStart DNA Master HybProbe kit (Roche Diagnostics GmbH). The RT-PCR assay reactions were performed using a LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics GmbH) in a 20 µl reaction volume. The primer sequences for the RagD gene were as follows: forward, 5'-GACAAAGTTCCTGGCTCTCG-3' and reverse, 5'-AGCACTCTAGGGGTCCCATT-3' (210 bp). Cycling conditions consisted of an initial denaturation period at 95˚C for 10 min, followed by 40 cycles at 95˚C for 10 sec, 62˚C for 10 sec and 72˚C for 9 sec.
Statistical analysis. Statistical analyses were conducted using the Mann-Whitney U test for unpaired samples and the Wilcoxon's singed rank test for paired samples. Linear relationships between variables were determined by means of simple linear regression. Correlation coefficients were determined by rank correlation using the Spearman's rho test and Chi-squared test. The overall survival of lung cancer patients was examined using the Kaplan-Meier analysis, and differences were examined using the log-rank test. The Stat-View software package (Abacus Concepts Inc., Berkeley, CA, USA) was used for all statistical analyses and P<0.05 was considered to indicate a statistically significant difference.
Results

NRF2 gene mutation in lung cancer.
Previously, we investigated the NRF2 gene mutation status in the N-terminal domain by direct sequencing (11) . A total of 291 non-small cell lung cancer (NSCLC) patients, including 148 lung squamous cell carcinoma patients, were investigated and 16 were identified to express NRF2 gene mutations. All of the mutations were identified in male patients with lung squamous cell carcinomas.
RagD mRNA levels in lung cancer patients. In this study, we investigated 90 lung squamous cell carcinoma patients, including 14 NRF2 mutant patients, in order to examine their Figure 1 . Overall survival was studied in reference to the RagD/β-actin mRNA level whether it was more or less than 2.14. Survival of the patients with high RagD/β-actin mRNA (11/21 resulted in mortlity; mean survival, 33.6 months) was significantly less than the patients with low MRP3/β-actin mRNA level (19/69 resulted in mortlity; mean survival, 85.0 months) (log-rank test, P= 0.0196). Table I . Clinicopathological data of 90 lung squamous cell carcinoma patients.
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RagD RagD/β-actin levels ( The overall survival of 90 lung squamous cell carcinoma patients, with follow-up until December 31, 2010, was studied in reference to the RagD/β-actin mRNA level. The survival of patients with high RagD/β-actin mRNA levels (11/21 mortalities; mean survival, 33.6 months) was significantly less compared to patients with low RagD/β-actin mRNA levels (19/68 mortalities; mean survival, 85.0 months) (log-rank test, P= 0.0196) (Fig. 1) . However, multivariate analysis demonstrated RagD mRNA was not an independent prognostic factor.
Discussion
In this study, we identified that RagD mRNA levels were correlated with advanced stage lung squamous cell carcinomas. We also demonstrated that high RagD mRNA levels correlated with poor prognosis using univariate analysis. Although the sample size was small, there was a tendency towards higher RagD mRNA levels in NRF2 mutant lung squamous cell carcinoma patients.
RagD is a member of the small G protein family gene, which encodes a recently discovered positive regulator of the mTOR pathway (8, 14, 15) , and is upregulated in NRF2 mutant cell lines. It has been demonstrated that RagD knockdown reduces the activation of mTOR signaling and NRF2 downregulation reduces RagD expression. Therefore, RagD plays an important role in the proliferation of NRF2-mutant cancer cells (9) . However, the putative promoter region of the RagD gene contains no ARE sequence, and chromatin immunoprecipitate sequence analyses has revealed that RagD is not a direct target of NRF2 (9) . An additional regulatory mediator may link the NRF2 gene and RagD.
The NRF2 gene is a master transcriptional activator of genes encoding a number of cytoprotective enzymes that are induced in response to environmental and endogenously derived oxidative/electrophilic agents (16) (17) (18) . A previous study demonstrated that RNAi-mediated silencing of NRF2 gene expression in NSCLC inhibited tumor growth (19) . A NRF2 gene promoter polymorphism has been identified and was suggested to correlate with carcinogenesis (20) . The correlation between NRF2 mutations and RagD mRNA levels of lung squamous cell carcinomas suggests a role of NRF2 in tumor growth. Constitutive expression of NRF2 may provide a survival advantage to invasive and metastatic cancer cells. NFR2 may adapt these cancer cells to the microenvironment by increasing chemoresistance under hypoxic conditions (21, 22) .
Higher RagD mRNA levels were correlated with poor prognosis, however, this may be due to the correlation with pathological stages. Our previous study demonstrated that mutant NRF2 had poor prognosis (11) , which confirmed results from other experiments (10, 12) . In addition, previous studies revealed that mTOR expression was a prognostic biomarker for poor survival of lung cancers (6, 7, 23) . A longer follow-up period and larger cohort are required to analyze RagD expression as a prognostic biomarker for lung cancers.
